Meropenem/vaborbactam activity in vitro: a new option for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae treatment.
Future Microbiol
; 16: 1261-1266, 2021 11.
Article
em En
| MEDLINE
| ID: mdl-34674551
Lay abstract Carbapenem-resistant Klebsiella pneumoniae is responsible, in critically ill patients, for nosocomial infections that are difficult to treat due to limited therapeutic options. Today, new antibiotics are available for treating these infections. The aim of this study is to evaluate the antimicrobial activity of meropenem/vaborbactam versus ceftazidime/avibactam. The results demonstrate that meropenem/vaborbactam could be an important turning point in the treatment of carbapenem-resistant K. pneumoniae infections, considering the emergence of ceftazidime/avibactam resistance.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ácidos Borônicos
/
Ceftazidima
/
Meropeném
/
Klebsiella pneumoniae
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Itália